Cisplatin

Generic Name: Cisplatin

Brand Names: Platinol

Drug Type: Small Molecule

Chemical Formula: Cl_₂H_₆N_₂Pt

CAS Number: 15663-27-1

Unique Ingredient Identifier: Q20Q21Q62J

Background: Cisplatin, cisplatinum or cis-diamminedichloroplatinum(II) (CDDP) is a platinum-based chemotherapy drug used to treat various types of cancers, including sarcomas, some carcinomas (e.g. small cell lung cancer, and ovarian cancer), lymphomas and germ cell tumors. It was the first member of its class, which now also includes carboplatin and oxaliplatin.

Indication: For the treatment of metastatic testicular tumors, metastatic ovarian tumors and advanced bladder cancer.

Associated Conditions: Advanced Ovarian Cancer, Ovarian Cancer Metastatic, Advanced Bladder cancer, Advanced Testicular cancer, Metastatic Testicular cancer

Associated Therapies: -

Clinical Trials

Dinutuximab With Chemotherapy, Surgery and Stem Cell Transplantation for the Treatment of Children With Newly Diagnosed High Risk Neuroblastoma

Phase 3

Recruiting

Conditions: Ganglioneuroblastoma, Nodular
Neuroblastoma

Interventions: Procedure: Biospecimen Collection
Procedure: Bone Marrow Aspiration
Procedure: Bone Marrow Biopsy
Drug: Carboplatin
Drug: Cisplatin
Procedure: Computed Tomography
Drug: Cyclophosphamide
Biological: Dinutuximab
Drug: Doxorubicin
Drug: Etoposide
Procedure: FDG-Positron Emission Tomography and Computed Tomography Scan
Procedure: Hematopoietic Cell Transplantation
Drug: Irinotecan
Drug: Isotretinoin
Procedure: Leukapheresis
Procedure: Magnetic Resonance Imaging
Drug: Melphalan
Radiation: Radiation Therapy
Procedure: Radionuclide Imaging
Other: Survey Administration
Drug: Temozolomide
Drug: Thiotepa
Drug: Topotecan
Procedure: Tumor Resection
Drug: Vincristine

First Posted Date: 2023-12-15

Last Posted Date: 2025-01-10

Lead Sponsor: National Cancer Institute (NCI)

Target Recruit Count: 478

Registration Number: NCT06172296

Locations: 🇺🇸
USA Health Strada Patient Care Center, Mobile, Alabama, United States
🇺🇸
Mercy Hospital Saint Louis, Saint Louis, Missouri, United States
🇺🇸
Children's Hospital of Alabama, Birmingham, Alabama, United States

and more 123 locations

Advanced First-line Treatment of Short-term Postoperative Progression of Head and Neck Squamous Cell Carcinoma

Phase 2

Recruiting

Conditions: Head and Neck Squamous Cell Carcinoma

Interventions: Drug: Camrelizumab
Drug: Cisplatin
Drug: Carboplatin
Drug: Lobaplatin
Drug: Nedaplatin
Radiation: Radiotherapy

First Posted Date: 2023-12-14

Last Posted Date: 2023-12-20

Lead Sponsor: Cancer Institute and Hospital, Chinese Academy of Medical Sciences

Target Recruit Count: 46

Registration Number: NCT06170697

Locations: 🇨🇳
Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, Beijing, China

Study of RAS(ON) Inhibitor Combinations in Patients with Advanced RAS-mutated NSCLC

Phase 1

Recruiting

Conditions: Non-Small Cell Lung Cancer, NSCLC
KRAS, NRAS, HRAS-mutated NSCLC
KRAS G12C-mutated Solid Tumors, Lung Cancer
Lung Cancer Stage IV, Advanced Solid Tumor, Cancer
RAS G12D-mutated NSCLC

Interventions: Drug: RMC-6291
Drug: RMC-6236
Drug: Pembrolizumab
Drug: Cisplatin
Drug: Carboplatin
Drug: Pemetrexed
Drug: RMC-9805

First Posted Date: 2023-12-08

Last Posted Date: 2025-01-07

Lead Sponsor: Revolution Medicines, Inc.

Target Recruit Count: 484

Registration Number: NCT06162221

Locations: 🇺🇸
City of Hope - Duarte, Duarte, California, United States
🇺🇸
New York University Langone Health, New York, New York, United States
🇮🇹
IRCCS Instituto Nazionale tumori Ragina Elena, Rome, Italy

and more 46 locations

A Trial to Learn if the Combination of Fianlimab, Cemiplimab, and Chemotherapy is Safe and Works Better Than the Combination of Cemiplimab and Chemotherapy in Adult Patients With Non-Small Cell Lung Cancer That Can be Treated With Surgery

Phase 2

Recruiting

Conditions: Resectable Non-small Cell Lung Cancer

Interventions: Drug: Fianlimab
Drug: Cemiplimab
Drug: Paclitaxel
Drug: Pemetrexed
Drug: Carboplatin
Drug: Cisplatin
Drug: Placebo

First Posted Date: 2023-12-07

Last Posted Date: 2024-11-27

Lead Sponsor: Regeneron Pharmaceuticals

Target Recruit Count: 180

Registration Number: NCT06161441

Locations: 🇺🇸
Mid Florida Hematology and Oncology Center, Orange City, Florida, United States
🇺🇸
Virginia Cancer Care Specialist, PC, Fairfax, Virginia, United States
🇦🇺
St Vincents Hospital, Fitzroy, Victoria, Australia

and more 20 locations

Evaluation of Concomitant Chemo-radiotherapy With Cisplatine vs Gemcitabin in Locally Advanced Cervicouterine Cancer

Phase 3

Recruiting

Conditions: Gemcitabine
Chemo-radiotherapy
Locally Advanced Cervical Cancer

Interventions: Drug: Gemcitabine
Drug: Cisplatin

First Posted Date: 2023-12-05

Last Posted Date: 2024-07-01

Lead Sponsor: National Institute of Cancerología

Target Recruit Count: 140

Registration Number: NCT06156514

Locations: 🇲🇽
National Cancer Institute of Mexico, México, Ciudad De México, Mexico

Beamion LUNG-2: A Study to Test Whether Zongertinib (BI 1810631) Helps People With Advanced Non-small Cell Lung Cancer With HER2 Mutations Compared With Standard Treatment

Phase 3

Recruiting

Conditions: Lung Cancer, Non-squamous, Non-small Cell

Interventions: Drug: zongertinib
Drug: pembrolizumab
Drug: cisplatin
Drug: carboplatin
Drug: pemetrexed

First Posted Date: 2023-11-30

Last Posted Date: 2025-01-09

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 270

Registration Number: NCT06151574

Locations: 🇨🇦
BC Cancer Agency - Vancouver, Vancouver, Canada
🇨🇦
Princess Margaret Cancer Centre, Toronto, Canada
🇨🇦
McGill University Health Centre (MUHC), Montreal, Canada

and more 110 locations

A Study of Xevinapant With Cisplatin and Radiation Therapy After Surgery in People With Head and Neck Cancer

Phase 2

Active, not recruiting

Conditions: Head and Neck Cancer

Interventions: Drug: Xevinapan
Drug: Cisplatin
Radiation: External beam

First Posted Date: 2023-11-24

Last Posted Date: 2024-08-23

Lead Sponsor: Memorial Sloan Kettering Cancer Center

Target Recruit Count: 4

Registration Number: NCT06145412

Locations: 🇺🇸
Memorial Sloan Kettering Bergen, Montvale, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Monmouth, Middletown, New Jersey, United States
🇺🇸
Memorial Sloan Kettering Basking Ridge, Basking Ridge, New Jersey, United States

and more 4 locations

Study to Evaluate the Safety and Efficacy of Daratumumab and Carfilzomib-based Induction/Consolidation/Maintenance Therapy in Transplant-eligible, Ultra High-risk, Newly Diagnosed Multiple Myeloma

Phase 2

Recruiting

Conditions: Multiple Myeloma
Extramedullary Multiple Myeloma
Primary Plasma Cell Leukemia

Interventions: Drug: Daratumumab
Drug: Carfilzomib
Drug: Lenalidomide
Drug: Dexamethasone
Drug: Cisplatin
Drug: epirubicin
Drug: Cyclophosphamide
Drug: Etoposide
Drug: Melphalan
Procedure: ASCT
Drug: bortezomib

First Posted Date: 2023-11-21

Last Posted Date: 2024-01-03

Lead Sponsor: Wuhan Union Hospital, China

Target Recruit Count: 54

Registration Number: NCT06140966

Locations: 🇨🇳
Institute of Hematology, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, Hubei, China

Pembrolizumab After Radiation Therapy and Chemotherapy in Limited Stage Small Cell Lung Cancer

Phase 2

Recruiting

Conditions: Stage I Lung Cancer
Stage II Lung Cancer
Limited Stage Lung Small Cell Carcinoma
Stage III Lung Cancer

Interventions: Drug: Cisplatin
Drug: Carboplatin
Drug: Etoposide
Biological: Pembrolizumab
Procedure: Computed Tomography
Procedure: Positron Emission Tomography
Procedure: Magnetic Resonance Imaging
Procedure: Biospecimen Collection
Radiation: Radiation Therapy

First Posted Date: 2023-11-20

Last Posted Date: 2024-05-22

Lead Sponsor: Vanderbilt-Ingram Cancer Center

Target Recruit Count: 20

Registration Number: NCT06140407

Locations: 🇺🇸
Vanderbilt University/Ingram Cancer Center, Nashville, Tennessee, United States

DAREON™-7: A Study to Test How Well Different Doses of BI 764532 in Addition to Chemotherapy Are Tolerated by People With Advanced Neuroendocrine Cancers

Phase 1

Recruiting

Conditions: Neuroendocrine Neoplasms

Interventions: Drug: BI 764532
Drug: Carboplatin
Drug: Etoposide
Drug: Cisplatin

First Posted Date: 2023-11-15

Last Posted Date: 2024-12-27

Lead Sponsor: Boehringer Ingelheim

Target Recruit Count: 55

Registration Number: NCT06132113

Locations: 🇺🇸
University of Miami, Miami, Florida, United States
🇧🇪
Brussels - UNIV Saint-Luc, Bruxelles, Belgium
🇧🇪
Edegem - UNIV UZ Antwerpen, Edegem, Belgium

and more 11 locations

Drug Development Updates

Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.

Home Terms & Conditions Privacy Policy